Delpharm in the news

The Delpharm plant in Saint-Remy-sur-Avre, France, commenced bottling BioNTech vaccines on April 9, 2021.

The Delpharm plant in Saint-Remy-sur-Avre, France, started bottling BioNTech vaccines on April 9, 2021.

Delpharm employees at the Huningue site are striking for the second time in two weeks over disagreements on annual salary negotiations and bonuses, despite the company's overall positive financial performance.

Delpharm employees in Huningue are striking for the second time in two weeks over unsatisfactory salary and bonus proposals during annual negotiations.

Stéphane Lepeu, Deputy General Manager and Commercial Director, is departing Delpharm and CDMO France after 15 years.

Delpharm Dijon is partnering in a pilot project to analyze and reduce the environmental impact of drug manufacturing processes through life cycle assessment.

The Delpharm pharmaceutical site in Gaillard marks 60 years, with full article access requiring a subscription.

Delpharm is investing $220 million to upgrade its Boucherville site with new equipment and expanded capacity for sterile injectable drugs, supported by government and private funding.

Quebec and federal governments, along with Delpharm, invest CAD 220 million to modernize Delpharm's Boucherville plant, supporting Sandoz's long-term supply of sterile injectables.

Delpharm's Boucherville plant is receiving CAD 220 million for modernization supported by government and private investment, backed by a 10-year supply deal with Sandoz.

Quebec is investing 60 million CAD to support Delpharm's 214.6 million CAD expansion of its Boucherville plant to boost sterile injectable production by 80%.

Delpharm is modernizing its Boucherville facility with a $220 million investment to expand capacity and strengthen pharmaceutical supply chains, preserving jobs and supporting local economy.

Delpharm is investing $215 million to modernize its Boucherville injectable drug plant with significant financial backing from the Quebec and federal governments.

Delpharm is investing $220 million, including $60 million from Québec, to modernize and expand its Boucherville sterile injectable drug manufacturing facility by 2031.

Quebec is providing $60 million in funding for a $214.6 million expansion of the Delpharm plant in Boucherville to boost injectable drug production.

Delpharm is investing $220 million by 2031 to modernize its Boucherville facility, enhancing sterile injectable drug production and preserving over 500 jobs in Québec.

French President Macron visited Delpharm's Saint-Rémy-sur-Avre site, which packages Pfizer/BioNTech COVID-19 vaccines, highlighting local investment and job creation.

Delpharm expanded its Saint-Rémy site with a €37 million sterile filling line, increasing capacity by 45 million 2ml vials annually.

Delpharm employees at Évreux strike over low pay raises and poor working conditions, reflecting wider unrest in the company.

Delpharm is investing 220 million CAD to modernize and expand its Canadian aseptic filling plant in Boucherville, supported by significant public funding.